Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Pavia – page 200

2 866 clinical trials in Pavia, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pavia at a glance
2 866
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

2 866 trials in Pavia

Open in trial search

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Liradasertib
  • Sponsor:Biogen Idec Research Limited

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of Vutrisiran and Patisiran for Patients with Hereditary Transthyretin Amyloidosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Malignant melanoma+1

Not recruiting

Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Naporafenib
  • Sponsor:Novartis Pharma AG

Study on Continued Ceritinib Treatment for Patients with ALK Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ceritinib
  • Sponsor:Novartis Pharma AG

Neuroendocrine tumour+1

Not recruiting

Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Octreotide
  • Sponsor:Advanced Accelerator Applications

Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of Zolbetuximab with Nab-Paclitaxel and Gemcitabine for Adults with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Herpes simplex

Not recruiting

Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Cidofovir
  • Sponsor:AiCuris Anti-infective Cures AG

Study of Pirtobrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Study on Asciminib and Asciminib Hydrochloride for Patients with Chronic Myelogenous Leukemia in Chronic Phase After Two or More Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib
  • Sponsor:Novartis Pharma AG

Study on the Effects of EVX-01 and Pembrolizumab in Adults with Advanced Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:EVX-01
  • Sponsor:Evaxion A/S

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Pavia

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on heart failure prevention and innovative treatments for cardiac conditions, including research on TTR amyloidosis and specialized therapies for pulmonary hypertension.

  • Heart Disease Prevention
  • Pulmonary Arterial Hypertension
  • Ventricular Tachycardia

Clinical trials evaluating new therapeutic approaches for cardiovascular complications and heart rhythm disorders.

02 Neurological Disorders

Studies investigating treatments for acute ischemic stroke and progressive neurological conditions, with particular focus on improving patient outcomes and functional recovery.

  • Stroke Treatment
  • Parkinson's Disease
  • Dravet Syndrome

Advanced research exploring innovative therapeutic approaches for various neurological conditions.

03 Autoimmune and Inflammatory Conditions

Research targeting chronic spontaneous urticaria, various forms of arthritis, and systemic autoimmune conditions affecting multiple organ systems.

  • Psoriatic Arthritis
  • Systemic Sclerosis
  • Immune System Disorders

Evaluation of novel therapies aimed at managing inflammatory responses and improving quality of life.

04 Respiratory Medicine

Comprehensive studies on chronic obstructive pulmonary disease and bronchiectasis, focusing on exacerbation prevention and symptom management.

  • COPD Treatment
  • Non-Cystic Fibrosis Bronchiectasis
  • Lung Fibrosis

Investigation of innovative therapeutic approaches for chronic respiratory conditions.

05 Hematology and Oncology

Advanced research in multiple myeloma and related blood disorders, including chronic myeloid leukemia and myelodysplastic syndromes.

  • Blood Cancers
  • Amyloidosis
  • Transfusion-Dependent Anemia

Development of targeted therapies for various hematological conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.